WO2005052182A3 - A method of analyzing plasma membrane protein content of cells - Google Patents

A method of analyzing plasma membrane protein content of cells Download PDF

Info

Publication number
WO2005052182A3
WO2005052182A3 PCT/IL2004/001085 IL2004001085W WO2005052182A3 WO 2005052182 A3 WO2005052182 A3 WO 2005052182A3 IL 2004001085 W IL2004001085 W IL 2004001085W WO 2005052182 A3 WO2005052182 A3 WO 2005052182A3
Authority
WO
WIPO (PCT)
Prior art keywords
plasma membrane
cells
protein content
membrane protein
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2004/001085
Other languages
French (fr)
Other versions
WO2005052182A2 (en
Inventor
Michal Linial
Alex Inberg
Yaniv Bledi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of WO2005052182A2 publication Critical patent/WO2005052182A2/en
Publication of WO2005052182A3 publication Critical patent/WO2005052182A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The present invention is of a method of characterizing proteins present on the plasma membrane of live cells which can be used in the identification of diagnostic markers and potentials drugs. Specifically, the present invention can be used to identify drug targets useful in treating disorders, such as cancer, which are associated with abnormal representation of cell surface proteins.
PCT/IL2004/001085 2003-11-26 2004-11-25 A method of analyzing plasma membrane protein content of cells Ceased WO2005052182A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52488503P 2003-11-26 2003-11-26
US60/524,885 2003-11-26

Publications (2)

Publication Number Publication Date
WO2005052182A2 WO2005052182A2 (en) 2005-06-09
WO2005052182A3 true WO2005052182A3 (en) 2005-07-07

Family

ID=34632938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/001085 Ceased WO2005052182A2 (en) 2003-11-26 2004-11-25 A method of analyzing plasma membrane protein content of cells

Country Status (1)

Country Link
WO (1) WO2005052182A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480235B (en) * 2020-12-14 2022-07-15 上海交通大学 A kind of biologically active peptide SGSAAWDDSAGGAGGQGLRVTAL and its preparation method and application

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
DE10341812A1 (en) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7879799B2 (en) 2006-08-10 2011-02-01 Institute For Systems Biology Methods for characterizing glycoproteins and generating antibodies for same
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2023049789A2 (en) * 2021-09-24 2023-03-30 Nitto Denko Corporation Yeast cells with reduced propensity to degrade acrylic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100892A1 (en) * 2001-05-29 2002-12-19 Regents Of The University Of Michigan Systems and methods for the analysis of proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100892A1 (en) * 2001-05-29 2002-12-19 Regents Of The University Of Michigan Systems and methods for the analysis of proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLEDI YANIV ET AL: "PROCEED: A proteomic method for analysing plasma membrane proteins in living mammalian cells.", BRIEFINGS IN FUNCTIONAL GENOMICS & PROTEOMICS, vol. 2, no. 3, October 2003 (2003-10-01), pages 254 - 265, XP002327557, ISSN: 1473-9550 *
BLONDER JOSIP ET AL: "Enrichment of integral membrane proteins for proteomic analysis using liquid chromatography-tandem mass spectrometry", JOURNAL OF PROTEOME RESEARCH, vol. 1, no. 4, July 2002 (2002-07-01), pages 351 - 360, XP002327558, ISSN: 1535-3893 *
WASHBURN MICHAEL P ET AL: "Large-scale analysis of the yeast proteome by multidimensional protein identification technology", NATURE BIOTECHNOLOGY, vol. 19, no. 3, March 2001 (2001-03-01), pages 242 - 247, XP002327559, ISSN: 1087-0156 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480235B (en) * 2020-12-14 2022-07-15 上海交通大学 A kind of biologically active peptide SGSAAWDDSAGGAGGQGLRVTAL and its preparation method and application

Also Published As

Publication number Publication date
WO2005052182A2 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
WO2004063362A3 (en) Cell cycle progression proteins
WO2003093469A3 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
WO2002084250A3 (en) Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples
WO2004044168A8 (en) Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities
WO2004070020A3 (en) Glyphosate tolerant alfalfa events and methods for detection thereof
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
WO2003048300A3 (en) Methods of identifying cellular target molecules
NZ598176A (en) Disintegrin variants and pharmaceutical uses thereof
WO2007133682A3 (en) 100% sequence identity detection methods for variable genomes
Maree et al. Trypanosoma brucei histones are heavily modified with combinatorial post-translational modifications and mark Pol II transcription start regions with hyperacetylated H2A
EP2051077A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002093129A3 (en) Methods for analyzing interactions between proteins in live and intact cells
WO2008019052A3 (en) Methods and compositions for identifying biomarkers
AU5419399A (en) Method for determining the immune defences of blood, test kit therefor and use of a suitable system for taking blood samples
WO2002079491A3 (en) Method for correlating gene expression profiles with protein expression profiles
WO2004087965A3 (en) Statistical analysis of regulatory factor binding sites of differentially expressed genes
WO2004065570A3 (en) Methods of metallizing nucleic acid molecules and methods of attaching nucleic acid molecules to conductive surfaces
WO2005052182A3 (en) A method of analyzing plasma membrane protein content of cells
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
Krobthong et al. The C‐terminally shortened analogs of a hexapeptide derived from Lingzhi hydrolysate with enhanced tyrosinase‐inhibitory activity
WO2005090393A3 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
WO2006036737A3 (en) Methods for identifying new drug leads and new therapeutic uses for known drugs
WO2004033485A3 (en) Nucleic acid supported protein complementation
WO2007128570A3 (en) In vitro method for the identification and early identification and for the concomitant monitoring of the therapy of drug- and addictive substance-induced liver damage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase